Document Detail

The potential role for lixivaptan in heart failure and in hyponatremia.
MedLine Citation:
PMID:  21548825     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Hypervolemia and hyponatremia are common features in heart failure and have been associated with increased morbidity and mortality. Stimulation of arginine vasopressin (AVP) plays an important role in the development of both hypervolemia and hyponatremia. Lixivaptan is a selective vasopressin type 2 (V(2)) receptor antagonist that has been demonstrated to have the ability to induce aquaresis, the electrolyte sparing excretion of water, resulting in fluid removal as well as correction of hyponatremia.
AREAS COVERED: This article describes the prevalence, pathophysiology and current treatment limitations of hyponatremia, highlights the importance of arginine vasopressin and the potential role of arginine vasopressin antagonists and reviews all available literature on lixivaptan, a selective V(2) receptor antagonist.
EXPERT OPINION: The available experience of lixivaptan in heart failure, although limited, is encouraging. Its aquaretic effect provides the basis for its use to correct hypervolemia and hyponatremia in patients with heart failure, and the absence of neurhormonal stimulation provides positive signal for the exploration of its potential in improving outcomes.
Hammam D Zmily; Nazia S Khan; Suleiman Daifallah; Jalal K Ghali
Related Documents :
17053905 - Diagnostic value of asymmetric striatal d2 receptor upregulation in parkinson's disease...
18303015 - Btb protein klhl12 targets the dopamine d4 receptor for ubiquitination by a cul3-based ...
8941175 - Dopamine d2 receptor imaging and neuroleptic drug response.
7870895 - Comparison of in vitro binding properties of a series of dopamine antagonists and agoni...
10779655 - Serotonin receptor subtypes involved in the spinal antinociceptive effect of 5-ht in rats.
18376415 - Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-09
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  20     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-11     Completed Date:  2011-09-06     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  831-48     Citation Subset:  IM    
Detroit Medical Center/Wayne State University, Harper University Hospital, 3990 John R, Suite 9370, Detroit, MI 48201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arginine Vasopressin / metabolism
Benzamides / adverse effects,  pharmacokinetics,  pharmacology*
Heart Failure / drug therapy*,  physiopathology
Hyponatremia / drug therapy*,  etiology
Plasma Volume / drug effects
Pyrroles / adverse effects,  pharmacokinetics,  pharmacology*
Receptors, Vasopressin / antagonists & inhibitors
Reg. No./Substance:
0/Benzamides; 0/Pyrroles; 0/Receptors, Vasopressin; 113-79-1/Arginine Vasopressin; 8F5X4B082E/lixivaptan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Measuring impact of environmental factors on human functioning and disability: a review of various s...
Next Document:  Production of Cloned and Transgenic Embryos Using Buffalo (Bubalus bubalis) Embryonic Stem Cell-Like...